Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

ALPHARETTA, GA - March 11, 2026 - PRESSADVANTAGE - Complete Family Healthcare recognizes 20 years of chiropractic and ...

Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy ...

Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD). But the company’s efforts to expand its use to a new indication is coming ...

China's tighter embrace of industrial policy in recent years has transformed its economy - and other countries are following suit Huang Yiping, a veteran Chinese economist, has attended countless ...

When closely related species mate, their offspring sometimes survive but cannot reproduce. This pattern often affects males ...

In a hotel room in Santa Clara, Calif., five members of the AI company Anthropic huddled around a laptop, working urgently. It was February 2025, and they had been at a conference nearby when they ...

Have you heard of Gen Alpha slang term?

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.